Drug intelligence / Profile preview

CZ10

Development stage: Phase 1
Lead developer: Nextrast
Modality: Small Molecules
Administration: Intravenous

Overview

CZ10 is a novel intravenous CT contrast material developed by Nextrast, Inc. It has demonstrated high safety and efficacy as an intravenous contrast agent in preclinical trials and is currently undergoing a Phase 1 clinical study to evaluate its safety, tolerability, pharmacokinetics, and initial effectiveness in healthy volunteers.

Other names: CZ-10CZ10CZ 10

Beyond the preview

Go deeper on CZ10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CZ10.

Explore the full profile